What Lafactin Treats: Main Uses and Benefits

Lafactin is relevant for symptomatic management across major depressive and anxiety domains, applied in situations involving certain distressing symptoms. It is commonly used to help with conditions such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder.

---

Therapeutic Support and Symptom Relief

This therapy is applied across domains where additional symptomatic support is needed; it plays a role in managing the overall symptom burden associated with conditions marked by increased physiological stress. It helps address symptom clusters that may become intense or disruptive, including persistent low mood, anhedonia, excessive worry, and acute panic manifestations. This assists with maintaining functional stability during symptomatic periods. The medication is also considered relevant in contexts marked by increased discomfort, providing supportive relief for symptoms related to heightened physiological activity, such as certain chronic pain and bothersome vasomotor symptoms (hot flashes).

“The primary aim is to support the patient during difficult episodes by easing distress, which contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Excessive Worry

---

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Scope

Lafactin is authorized for use in adults, defined as individuals 18 years of age and older. It is formally not approved and not recommended for the pediatric population. The medicine is strictly contraindicated for patients with a known hypersensitivity to the drug or its components, or for those concurrently taking a Monoamine Oxidase Inhibitor (MAOI).

Eligibility-Related Restrictions

Use is conditional upon the status of organ function. Patients with any degree of renal or hepatic impairment are required to have their total daily dose adjusted. Specific caution and monitoring are mandated for individuals with a history of mania/hypomania, uncontrolled hypertension (which must be controlled before starting treatment), or conditions such as a risk of angle-closure glaucoma.

Physiological Status

During the third trimester of pregnancy, use may increase the risk for symptoms of poor neonatal adaptation in the infant. For lactation, regulatory documents state that venlafaxine is excreted into breast milk, and the decision requires carefully weighing the importance of the drug to the mother against the potential risks to the infant.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Lafactin by establishing absolute prohibitions for certain concomitant substances and allergies. Eligibility is otherwise classified as conditional or restricted based on age, organ function status, and the presence of specific pre-existing clinical conditions.

Interactions with other medicines and products

The regulatory profile for Lafactin (Venlafaxine) establishes strict interaction-related constraints across pharmacokinetic and pharmacodynamic domains.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited by regulatory agencies due to the high risk of serotonin syndrome. This prohibition necessitates a mandated separation period: Lafactin must not be initiated for at least 14 days after discontinuing an MAOI, and an MAOI must not be initiated for at least 7 days after discontinuing Lafactin.

Pharmacodynamic and Pharmacokinetic Constraints

• Serotonergic Risk: An additive pharmacodynamic risk for serotonin syndrome is documented when Lafactin is co-administered with other serotonergic agents (e.g., Triptans, SSRIs).
• Bleeding Risk: Co-administration with drugs that interfere with hemostasis, such as NSAIDs, Aspirin, and Warfarin, is noted to increase the documented risk of bleeding events.
• Exposure Modification: Co-administration with inhibitors of CYP2D6 and CYP3A4 (e.g., Ketoconazole) is shown to increase the systemic exposure of Lafactin and its active metabolite.
• Population Note: The interaction with Cimetidine, which inhibits metabolism, is explicitly documented as being more pronounced in patients with hepatic or renal impairment.

Substance Restrictions

Consumption of alcohol is restricted with the extended-release product as it increases the rate of drug release. Concomitant use with Tryptophan supplements and the herbal product St. John's Wort is officially not recommended due to the potential for increased serotonergic activity.

How Lafactin Works

Lafactin's mechanism involves targeting key regulatory systems, leading to a reduction in pathway activity and altered homeostatic signaling dynamics.

Primary Interaction with G-Protein Coupled Receptors

Lafactin acts as a modulator at specific G-protein coupled receptors ( GPCRs) on neural cells, which are central to neurotransmitter signaling. This initial binding event alters the receptor's activity, modulating signal transduction within defined neural systems.

Modulating Downstream Signaling Cascades

The initial receptor interaction triggers changes in intracellular signaling cascades and second messenger systems. By modifying these early molecular steps, Lafactin alters the flow of information within the cell, engaging mechanisms that influence feedback regulation within key pathways and adjusting the regulatory dynamics of processes driven by distinct signaling patterns.

Reduction of Physiological Pathway Activity

These mechanistic domains act upon autonomic or limbic regulatory systems. This focused reduction of signaling modifies the rate of activity within targeted pathways, influencing the equilibrium of physiological processes.

How to Use Lafactin

Lafactin, which contains Venlafaxine, is administered via the oral route using immediate-release tablets or, more commonly, Extended-Release (ER) capsules and tablets. The ER form is taken once daily and is consumed with food to ensure its correct absorption and usage pattern.

---

Official Dosing and Administration Protocol

Dosing ranges for Lafactin ER are established based on the clinical scenario. Treatment typically starts with a low dose, such as 75 mg once daily for most conditions, or 37.5 mg for the first week when managing Panic Disorder. The maximum labeled dose for most adult indications, including Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), is 225 mg per day.

---

Administration Requirements and Adjustments

Lafactin ER is swallowed whole and is not divided, crushed, chewed, or dissolved. If swallowing is difficult, some formulations allow the capsule contents to be sprinkled onto a small amount of applesauce and swallowed immediately without chewing.

For patients with pre-existing organ function impairment, specific dose reductions are applied: those with mild to moderate hepatic impairment generally require a 50% reduction in the total daily dose, and those with severe renal impairment may require a reduction of 50% or more. Treatment cessation involves a gradual dose reduction (tapering), typically in 75 mg decrements per week, rather than abrupt discontinuation, to manage the transition from therapy.

Research evidence / Overview of studies for Lafactin

This section provides an overview of the types of clinical studies that have been conducted on Lafactin (Venlafaxine). The available evidence contributes to the broader evidence landscape by describing observed symptom patterns and outcomes. Research provides context but not individual predictions.

---

Evidence for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

The evaluation of Lafactin for MDD primarily relied on short-term, placebo-controlled Randomized Controlled Trials (RCTs), typically 8 to 12 weeks, which examined outcomes like depression severity scores and symptom resolution in adult outpatients. Research for GAD also involved short- and intermediate-term RCTs, focusing on outcomes related to systemic or functional imbalance, such as anxiety severity scales and measures of daily functioning. Lafactin was also evaluated in associated conditions like Social Anxiety Disorder (SAD), Panic Disorder, and for Vasomotor Symptoms (VMS) in postmenopausal women, with studies tracking changes in symptom frequency and severity.

---

Long-term Follow-up and Specific Populations

Extended-duration research was evaluated in the context of preventing symptom recurrence in MDD and relapse in GAD, monitoring participants over periods up to a year or longer. The evidence contributes to understanding symptom patterns and outcomes reflecting daily functioning in observed populations. Studies also examined specific groups, including older adults and those with comorbid conditions (e.g., MDD co-occurring with GAD). However, Lafactin was evaluated in pediatric populations, but regulatory summaries note that studies have not consistently demonstrated a pattern of outcomes in children for MDD, and GAD findings were mixed.

---

What Research Gaps and Uncertainty Remain

Scientific reviews highlight several areas where evidence is limited or certainty remains low. A major limitation is that the results of primary evaluation trials typically apply only to the populations studied in short-term outcomes. Data describing how symptoms evolve over multi-year periods are still emerging and are not fully established. Furthermore, comparative evidence is lacking (studies directly comparing Lafactin to other treatments) in the overall research landscape.

Common questions about Lafactin (FAQ)

Q: What is Lafactin and what is it used for?

Lafactin is the brand name for the drug venlafaxine, an antidepressant medication. It belongs to a class of drugs called serotonin and norepinephrine reuptake inhibitors (SNRIs).

It is primarily used to treat major depressive disorder (MDD). It is also approved for treating other conditions, including:

• Generalized Anxiety Disorder (GAD)
• Social Anxiety Disorder (SAD or social phobia)
• Panic Disorder

Q: How does Lafactin work in the body?

Lafactin (venlafaxine) works by affecting certain chemical messengers in the brain called neurotransmitters, specifically serotonin and norepinephrine.

It works by blocking the reuptake (reabsorption) of these two neurotransmitters by nerve cells, which leads to an increase in their levels in the brain. Increasing the availability of serotonin and norepinephrine is thought to help improve mood and reduce anxiety in people with depression and anxiety disorders.

Q: How long does it take for Lafactin to start working?

It may take several weeks before you feel the full benefit of Lafactin. You might start noticing some improvement in symptoms, such as sleep, appetite, or energy, within the first 1 to 2 weeks.

However, it can take 4 to 8 weeks to feel the full effects on mood and other primary symptoms of depression or anxiety. It is important to continue taking the medication exactly as prescribed, even if you do not see immediate results.

Q: What are some common side effects of Lafactin?

Common side effects of Lafactin are generally mild and may decrease over time as your body adjusts to the medication. These may include:

• Nausea
• Headache
• Drowsiness or fatigue
• Dizziness
• Insomnia (trouble sleeping)
• Dry mouth
• Constipation
• Sweating

If you experience side effects that are severe or do not go away, you should discuss them with your healthcare provider.

Q: Is it safe to stop taking Lafactin suddenly?

No, you should never stop taking Lafactin suddenly without first talking to your healthcare provider. Abruptly stopping this medication can lead to withdrawal symptoms, which are often referred to as Antidepressant Discontinuation Syndrome. Symptoms can include:

• Dizziness, lightheadedness, or vertigo
• Nausea and vomiting
• Headache
• Trouble sleeping or vivid dreams
• Anxiety, agitation, or confusion
• A sensation like an electric shock (sometimes called 'brain zaps')

If your healthcare provider decides that you should stop taking Lafactin, they will guide you through a gradual reduction (tapering) of the dose to help prevent or minimize these withdrawal effects.

Lafactin (venlafaxine) must be stored and handled according to regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

Most formulations require storage at Controlled Room Temperature (CRT), typically defined as 20 C to 25 C (68 F to 77 F). The product must be kept away from moisture, excessive heat, and direct light.

Handling Constraint	Requirement
Temperature	Keep from freezing; do not store above 30 C.
Container	Store in a closed container and/or the original package.
Child Safety	Must be kept out of the reach of children.

Disposal Instructions

Outdated or unused medicine must not be kept. Regulatory instructions require patients to ask a healthcare professional or pharmacist how to dispose of any unused Lafactin. Disposal must be conducted in accordance with local regulatory requirements for pharmaceutical waste.